Understanding and harnessing triple-negative breast cancer-related microbiota in oncology
- PMID: 36505861
- PMCID: PMC9730816
- DOI: 10.3389/fonc.2022.1020121
Understanding and harnessing triple-negative breast cancer-related microbiota in oncology
Abstract
Bacterial inhabitants of the body have the potential to play a role in various stages of cancer initiation, progression, and treatment. These bacteria may be distal to the primary tumour, such as gut microbiota, or local to the tissue, before or after tumour growth. Breast cancer is well studied in this context. Amongst breast cancer types, Triple Negative Breast Cancer (TNBC) is more aggressive, has fewer treatment options than receptor-positive breast cancers, has an overall worse prognosis and higher rates of reoccurrence. Thus, an in-depth understanding of the bacterial influence on TNBC progression and treatment is of high value. In this regard, the Gut Microbiota (GM) can be involved in various stages of tumour progression. It may suppress or promote carcinogenesis through the release of carcinogenic metabolites, sustenance of proinflammatory environments and/or the promotion of epigenetic changes in our genome. It can also mediate metastasis and reoccurrence through interactions with the immune system and has been recently shown to influence chemo-, radio-, and immune-therapies. Furthermore, bacteria have also been found to reside in normal and malignant breast tissue. Several studies have now described the breast and breast tumour microbiome, with the tumour microbiota of TNBC having the least taxonomic diversity among all breast cancer types. Here, specific conditions of the tumour microenvironment (TME) - low O2, leaky vasculature and immune suppression - are supportive of tumour selective bacterial growth. This innate bacterial ability could enable their use as delivery agents for various therapeutics or as diagnostics. This review aims to examine the current knowledge on bacterial relevance to TNBC and potential uses while examining some of the remaining unanswered questions regarding mechanisms underpinning observed effects.
Keywords: bacterial theranostics; microbiome; microbiome & dysbiosis; microbiome modulation; triple-negative-breast-cancer.
Copyright © 2022 Devoy, Flores Bueso and Tangney.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures



Similar articles
-
Obesity Modulates the Gut Microbiome in Triple-Negative Breast Cancer.Nutrients. 2021 Oct 19;13(10):3656. doi: 10.3390/nu13103656. Nutrients. 2021. PMID: 34684657 Free PMC article.
-
Therapeutic Potential of Thymoquinone in Triple-Negative Breast Cancer Prevention and Progression through the Modulation of the Tumor Microenvironment.Nutrients. 2021 Dec 25;14(1):79. doi: 10.3390/nu14010079. Nutrients. 2021. PMID: 35010954 Free PMC article. Review.
-
Body Microbiota and Its Relationship With Benign and Malignant Breast Tumors: A Systematic Review.Cureus. 2022 May 30;14(5):e25473. doi: 10.7759/cureus.25473. eCollection 2022 May. Cureus. 2022. PMID: 35783895 Free PMC article. Review.
-
Influence of the gut microbiota on immune cell interactions and cancer treatment.J Transl Med. 2024 Oct 15;22(1):939. doi: 10.1186/s12967-024-05709-3. J Transl Med. 2024. PMID: 39407240 Free PMC article. Review.
-
Systems Medicine Design for Triple-Negative Breast Cancer and Non-Triple-Negative Breast Cancer Based on Systems Identification and Carcinogenic Mechanisms.Int J Mol Sci. 2021 Mar 17;22(6):3083. doi: 10.3390/ijms22063083. Int J Mol Sci. 2021. PMID: 33802957 Free PMC article.
Cited by
-
Beyond Tumor Borders: Intratumoral Microbiome Effects on Tumor Behavior and Therapeutic Responses.Immune Netw. 2024 Dec 9;24(6):e40. doi: 10.4110/in.2024.24.e40. eCollection 2024 Dec. Immune Netw. 2024. PMID: 39801738 Free PMC article. Review.
-
Elucidating the Intricate Roles of Gut and Breast Microbiomes in Breast Cancer Metastasis to the Bone.Cancer Rep (Hoboken). 2024 Aug;7(8):e70005. doi: 10.1002/cnr2.70005. Cancer Rep (Hoboken). 2024. PMID: 39188104 Free PMC article. Review.
-
A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer.J Adv Res. 2023 Dec;54:271-292. doi: 10.1016/j.jare.2023.02.005. Epub 2023 Feb 14. J Adv Res. 2023. PMID: 36791960 Free PMC article. Review.
-
Bacterial-Mediated In Situ Engineering of Tumour-Associated Macrophages for Cancer Immunotherapy.Cancers (Basel). 2025 Feb 20;17(5):723. doi: 10.3390/cancers17050723. Cancers (Basel). 2025. PMID: 40075571 Free PMC article. Review.
-
Bacteriome and mycobiome dysbiosis in oral mucosal dysplasia and oral cancer.Periodontol 2000. 2024 Oct;96(1):95-111. doi: 10.1111/prd.12558. Epub 2024 Mar 19. Periodontol 2000. 2024. PMID: 38501658 Free PMC article. Review.
References
-
- National Cancer Institute (NCI) . Surveillance epidemiology, end results (SEER) program: SEER*Stat database: Incidence - SEER research data, Nov 2018 Sub (1975-2016) <Katrina/Rita population adjustment> - linked to county attributes - total U.S., 1969-2017 counties, national cancer institute, DCCPS, surveillance research program. November 2018;based on the November 2018 submission. Bethesda, MD: NCI; (2018).
-
- Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA, et al. . Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Instit (2015) 107(6):djv048. doi: 10.1093/jnci/djv048 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources